ArticleAsian Pacific journal of cancer prevention : APJCP2023
Analysis of E-cadherin (CDH1) Gene Polymorphism and Its Association with Cervical Cancer Risk in Bangladeshi Women.
Article in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- DNA methylation biomarkers as an early diagnostic tool in the progression of oral squamous cell carcinoma.Journal of oral and maxillofacial pathology : JOMFPArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundE-cadherin (CDH1), a tumor suppressor gene, encodes a transmembrane glycoprotein that helps in maintaining squamous epithelium integrity of the cervix. We aimed to investigate the association between -160C/A genetic polymorphism in CDH1 and the risk of cervical cancer in Bangladeshi females.
methodThe present case-control study included 117 cervical cancer cases and 147 age-matched controls. The genomic DNA was extracted from peripheral blood and genotyped by using PCR-RFLP analysis.
resultsGenotyping results demonstrated that the occurrences of normal homozygous (-160C/C), heterozygous (-160C/A) and variant homozygous (-160A/A) genotypes were 64.10, 27.35 and 8.55% in cases, and 77.55, 19.73 and 2.72% in controls, respectively. Compared to normal C/C genotype, variant A/A and combined (C/A+A/A) or 'any A' genotypes exhibited 3.80-fold (95% CI=1.150-12.561, P=0.029) and 1.93-fold (95% CI=1.126-3.323, P=0.017) increased risk of cervical cancer development. The -160C allele was found to be positively linked to cervical cancer incidence and raised the risk by 1.81-fold (OR= 1.814, 95% CI=1.152-2.857, p=0.01). Moreover, women carrying -160A/A variant homozygosity along with an early marital history (<18 years) were more susceptible to cervical cancer development (χ2 =6.605, p=0.037).
conclusionThe study suggests that the (A/A) and combined (C/A +A/A) genotypes are associated with greater risk of cervical cancer in Bangladeshi women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.